Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factorealfa antagonists Part II. Screening for patients on tumor necrosis factor- alfa antagonists

被引：0
作者：
Chirch, Lisa M. [1 ]
Cataline, Philip R. [1 ]
Dieckhaus, Kevin D. [1 ]
Grant-Kels, Jane M. [2 ,3 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06032 USA
[2] Univ Connecticut, Ctr Hlth, Div Infect Dis, Farmington, CT 06032 USA
[3] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT 06032 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2014年 / 71卷 / 01期
关键词：
biologic therapy; immunizations; opportunistic infection; psoriasis; tumor necrosis factor; FACTOR THERAPY; PSORIATIC-ARTHRITIS; ETANERCEPT THERAPY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Tumor necrosis factorealfa levels are linked to disease severity in patients with inflammatory conditions, such as psoriasis. Inhibitors of this cytokine are commonly used with significant success in the treatment of such inflammatory disorders. Their use, however, can be plagued by infectious complications. An awareness of potential infections associated with these therapies is critical in order to maximize preventive efforts both before and during therapy. This review provides a guide for dermatologists caring for patients in need of this type of biologic therapy to preemptively address the infectious risks. Part II of this continuing medical education article reviews recommended screening methods for patients undergoing evaluations for tumor necrosis factor inhibitor therapy for psoriasis or other dermatologic diseases, and discusses possible prophylactic strategies to use, including the appropriate use of immunizations.
引用
收藏
页数：7
相关论文
共 24 条
  • [1] AIDSinfo, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Secondary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2019
  • [2] Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
  • [3] Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626
  • [4] [Anonymous], 2006, ZOSTAVAX PACK INS
  • [5] Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
  • [6] Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
    Bergstrom, L
    Yocum, DE
    Ampel, NM
    Villanueva, I
    Lisse, J
    Gluck, O
    Tesser, J
    Posever, J
    Miller, M
    Araujo, J
    Kageyama, DM
    Berry, M
    Karl, L
    Yung, CM
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (06): : 1959 - 1966
  • [7] *CDCP, 2013, MMWR-MORBID MORTAL W, V62, P9
  • [8] Centers for Disease Control and Prevention, VACC IMM
  • [9] Centers for Disease Control and Prevention, 2011, PINK BOOK, V60, P1
  • [10] Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1705
123